Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb;82(3):251-274.
doi: 10.1007/s40265-021-01670-3. Epub 2022 Feb 8.

Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder

Elizabeth M Burnette  1   2 , Steven J Nieto  1 , Erica N Grodin  1 , Lindsay R Meredith  1 , Brian Hurley  3 , Karen Miotto  4 , Artha J Gillis  4 , Lara A Ray  5   6
Affiliations
Review

Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder

Elizabeth M Burnette et al. Drugs. 2022 Feb.

Abstract

Alcohol use disorder (AUD) is a highly prevalent but severely under-treated disorder, with only three widely-approved pharmacotherapies. Given that AUD is a very heterogeneous disorder, it is unlikely that one single medication will be effective for all individuals with an AUD. As such, there is a need to develop new, more effective, and diverse pharmacological treatment options for AUD with the hopes of increasing utilization and improving care. In this qualitative literature review, we discuss the efficacy, mechanism of action, and tolerability of approved, repurposed, and novel pharmacotherapies for the treatment of AUD with a clinical perspective. Pharmacotherapies discussed include: disulfiram, acamprosate, naltrexone, nalmefene, topiramate, gabapentin, varenicline, baclofen, sodium oxybate, aripiprazole, ondansetron, mifepristone, ibudilast, suvorexant, prazosin, doxazosin, N-acetylcysteine, GET73, ASP8062, ABT-436, PF-5190457, and cannabidiol. Overall, many repurposed and novel agents discussed in this review demonstrate clinical effectiveness and promise for the future of AUD treatment. Importantly, these medications also offer potential improvements towards the advancement of precision medicine and personalized treatment for the heterogeneous AUD population. However, there remains a great need to improve access to treatment, increase the menu of approved pharmacological treatments, and de-stigmatize and increase treatment-seeking for AUD.

PubMed Disclaimer

Conflict of interest statement

The authors declare they have no conflict of interest.

References

    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders [Internet]. 5th ed. American Psychiatric Association; 2013 [cited 2021 Mar 15]. 10.1176/appi.books.9780890425596.
    1. Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, et al. Epidemiology of DSM-5 alcohol use disorder: results from the national epidemiologic survey on alcohol and related conditions III. JAMA Psychiat. 2015;72(8):757–766. - PMC - PubMed
    1. Degenhardt L, Charlson F, Ferrari A, Santomauro D, Erskine H, Mantilla-Herrara A, et al. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry. 2018;5(12):987–1012. - PMC - PubMed
    1. World Health Organization. Global status report on alcohol and health 2014. World Health Organization; 2014.
    1. Stahre M, Roeber J, Kanny D, Brewer RD, Zhang X. Contribution of excessive alcohol consumption to deaths and years of potential life lost in the United States. Prev Chronic Dis. 2014;26(11):E109. - PMC - PubMed